| 摘要 |
PURPOSE: A composition for treating Epstein-Barr virus-positive gastric cancer is provided to suppress proliferation of Epstein-Barr virus and to effectively treat Epstein-Barr virus-positive gastric cancer when ganciclovir and gemcitabine are combined. CONSTITUTION: A pharmaceutical composition for treating Epstein-Barr virus-positive gastric cancer contains an anti-herpes viral agent and 1 ng/ml or greater of gemcitabine. The anti-herpes viral agent is selected among ganciclovir, acyclovir, penciclovir, vidarabine, idoxuridine, trifluridine, edoxudine, brivudin, and cytarabine. The pharmaceutical composition contains 160 ng/ml of gemcitabine. A method for inducing lytic infection of Epstein-Barr virus comprises the step of administering at least 1 ng/mg of gemcitabine to a subject. |
